Quantcast

Latest Natalizumab Stories

2008-09-19 15:00:12

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that a post-hoc analysis showed TYSABRI(R) (natalizumab) treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo. This post-hoc analysis provides the first evidence that TYSABRI is associated with a significant improvement in functional outcome, rather than only slowing or preventing progression of disability, in those living with relapsing...

2008-09-18 15:00:38

Biogen Idec (NASDAQ: BIIB) today announced that data was presented from the ASSURANCE (ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs) study, showing the long-term benefits of AVONEX(R) (interferon beta-1a IM) therapy in patients with relapsing multiple sclerosis (MS) for up to 15 years. The ASSURANCE study represents the long-term follow-up of patients who participated in the Multiple Sclerosis Collaborative Research Group (MSCRG), the original Phase III pivotal trial...

2008-09-18 09:00:49

Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada. Nearly 20 presentations will focus on the company's products: TYSABRI(R) (natalizumab), which offers MS patients a new level of efficacy, and AVONEX(R) (Interferon beta-1a), the most prescribed MS therapy worldwide, as well as its pipeline featuring compounds targeting...

2008-09-08 21:00:04

WASHINGTON - The government on Friday began posting a list of prescription drugs under investigation for potential safety problems in an effort to better inform doctors and patients. The first list is a bare-bones compilation naming 20 medications and the potential issue for each. It provides no indication of how widespread or serious the problems might be, leading some consumer advocates to question its usefulness, and prompting industry worries that skittish patients might stop taking a...

2008-09-08 18:00:04

WASHINGTON - The government on Friday began posting a list of prescription drugs under investigation for potential safety problems in an effort to better inform doctors and patients. The first list is a bare-bones compilation naming 20 medications and the potential issue for each. It provides no indication of how widespread or serious the problems might be, leading some consumer advocates to question its usefulness, and prompting industry worries that skittish patients might stop taking a...

23db77088110ba987d530696a135fc2e1
2008-09-08 14:10:00

In an effort to better inform doctors and patients of certain risks, the government on Friday began posting a list of prescription drugs under investigation for potential safety problems. The first list names 20 medications and the potential issue for each, but provides no indication of how widespread or serious the problems might be, leading some consumer advocates to question its usefulness, and prompting industry worries that skittish patients might stop taking a useful medication if they...

2008-09-05 06:00:23

Elan and Biogen Idec have initiated the first clinical trial of Tysabri in oncology. The first dose of Tysabri was administered earlier in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. This Phase I/II, open-label, two-arm study is designed to evaluate the safety and anti-tumor activity of Tysabri in patients with relapsed or refractory multiple myeloma. In...

2008-09-05 03:00:06

Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today announced the initiation of the first clinical trial of TYSABRI(R) (natalizumab) in oncology. The first dose of TYSABRI was administered yesterday in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of TYSABRI in patients with relapsed or refractory multiple myeloma. TYSABRI is a recombinant, humanized monoclonal antibody that targets the adhesion molecule VLA4...

2008-08-20 09:01:30

SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) therapies. Biogen/Elan's Tysabri has been under scrutiny due to two additional reported cases of PML, a rare and potentially fatal brain disease associated with use of the drug. MedPredict recently...

2008-07-23 12:01:11

Biogen Idec has reported total revenue of $993 million for the second quarter of 2008, an increase of 28% compared to total revenue of $773 million for the same quarter of 2007. The company posted a net income of $207 million in the second quarter of 2008, an increase of 11% compared to $186 million in the second quarter of 2007. Second quarter 2008 diluted earnings per share (EPS) was $0.70, an increase of 30% from $0.54 reported in the second quarter of 2007. James Mullen, Biogen...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related